








ROBUST PIPELINE OF SWITCH-CONTROL KINASE INHIBITORS

		PRE-CLINICAL	PHASE 1	PHASE 1/2	PHASE 3	REGULATORY SUBMISSION	APPROVED	COMMERCIAL RIGHTS	
 (ripretinib) 50mg tablets Broad-Spectrum Inhibitor of KIT and PDGFRA	GIST ≥4 th Line (INVICTUS Study)						 + Global Approvals ²		 ¹
Vimseltinib Selective Inhibitor of CSF1R	TGCT (Phase 3 MOTION Study)								
	TGCT (Phase 1/2 Study)								
DCC-3116 Selective Inhibitor of ULK	RAS/MAPK Mutant Cancers In Combination with Trametinib, Binimetinib, or Sotorasib								
Pan-RAF Program Inhibitor of RAF Kinases	Solid Tumors								
VPS34 Program Selective Inhibitor of VPS34	Solid Tumors							 ³	



Notes: CSF1R=colony-stimulating factor 1 receptor; GIST=gastrointestinal stromal tumor; KIT=KIT proto-oncogene receptor tyrosine kinase; MAPK=mitogen-activated protein kinase; PDGFRA=platelet-derived growth factor receptor α ; RAF=rapidly accelerated fibrosarcoma; RAS=rat sarcoma gene; TGCT=tenosynovial giant cell tumor; ULK=unc-51-like autophagy-activating kinase; (1) Exclusive development and commercialization license with Zai Lab in Greater China for QINLOCK; (2) QINLOCK is approved for 4th line GIST in the United States, Australia, Canada, China, European Union, Hong Kong, Switzerland, Taiwan, and the United Kingdom; (3) Agreement with Sprint Bioscience for exclusive in-license worldwide rights to a research-stage program targeting VPS34.